Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BCG-Unresponsive Bladder Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)WithdrawnNCT04109092
What this trial is testing

Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Who this might be right for
Urinary Bladder Neoplasms
Eisai Inc.
Testing effectiveness (Phase 2)Ended earlyNCT03519256
What this trial is testing

Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Who this might be right for
Urinary Bladder Neoplasms
Bristol-Myers Squibb 142
Testing effectiveness (Phase 2)Ended earlyNCT01625260
What this trial is testing

ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer
Altor BioScience 12
Testing effectiveness (Phase 2)Study completedNCT00003129
What this trial is testing

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

Who this might be right for
Bladder Cancer
Eastern Cooperative Oncology Group 75
Testing effectiveness (Phase 2)Study completedNCT04172675
What this trial is testing

Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Who this might be right for
Urinary Bladder Neoplasms
Janssen Research & Development, LLC 107
Large-scale testing (Phase 3)Ended earlyNCT02982395
What this trial is testing

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Who this might be right for
Non Muscle Invasive Bladder Cancer
Samyang Biopharmaceuticals Corporation 36
Not applicableEnded earlyNCT06026332
What this trial is testing

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

Who this might be right for
Bladder Cancer
Ferring Pharmaceuticals 202
Early research (Phase 1)Study completedNCT01162785
What this trial is testing

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

Who this might be right for
Bladder Cancer
M.D. Anderson Cancer Center 7
Early research (Phase 1)Study completedNCT03053635
What this trial is testing

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
Theralase® Technologies Inc. 6
Large-scale testing (Phase 3)Active Not RecruitingNCT04452591
What this trial is testing

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
CG Oncology, Inc. 190
Large-scale testing (Phase 3)Study completedNCT01316874
What this trial is testing

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)

Who this might be right for
Carcinoma in SituBladder Cancer
Endo USA Inc., a Keenova Therapeutics Company 90
Large-scale testing (Phase 3)Looking for participantsNCT06545955
What this trial is testing

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals 250
Large-scale testing (Phase 3)Study completedNCT00406068
What this trial is testing

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Neoplasms
Bioniche Life Sciences Inc. 129
Testing effectiveness (Phase 2)Active Not RecruitingNCT02202772
What this trial is testing

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

Who this might be right for
Urothelial Carcinoma of the Urinary Bladder
Guarionex J. Decastro 51
Large-scale testing (Phase 3)WithdrawnNCT02471495
What this trial is testing

RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)

Who this might be right for
Bladder Cancer
Medical Enterprises Europe B.V.
Early research (Phase 1)Study completedNCT04798703
What this trial is testing

Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)

Who this might be right for
Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a. 20
Testing effectiveness (Phase 2)UnknownNCT03950362
What this trial is testing

Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle-invasive Bladder Cancer
Institut Paoli-Calmettes 67
Testing effectiveness (Phase 2)Looking for participantsNCT06388720
What this trial is testing

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

Who this might be right for
Bladder Cancer
National Cancer Center, Korea 82
Large-scale testing (Phase 3)WithdrawnNCT07342517
What this trial is testing

NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urothelial Carcinoma Bladder+2 more
Relmada Therapeutics, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06971614
What this trial is testing

T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

Who this might be right for
Nonmuscle-invasive Bladder Cancer
ImmVira Pharma Co. Ltd 160
Next Page